Healthcare solutions company Owens & Minor Inc (NYSE:OMI) on Tuesday introduced ByramConnect, a digital health platform designed to support Byram Healthcare customers managing diabetes and other chronic conditions.
Powered by the Welldoc App, the platform offers AI-driven health coaching, self-tracking and personalised insights to improve patient outcomes.
ByramConnect is an FDA-cleared class II software as a medical device intended for patients with type 1 or type 2 diabetes. Clinical studies show that users experienced improvements in A1C levels, blood pressure and weight management. The app integrates data from fitness trackers, glucose monitors, blood pressure monitors and other connected health devices.
Key features include AI-driven digital coaching, diet and nutrition support, GLP-1 medication tracking and mental well-being guidance. Patients receive personalised health reports with actionable insights to share with their healthcare providers.
The platform is available at no additional cost exclusively to Byram Healthcare diabetes customers. Eligible users will receive email invitations with an access code to download the app on iOS and Android devices.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval